Advertisement

Calcium oxalate supersaturation increases early after Roux-en-Y gastric bypass

      Abstract

      Background

      Calcium oxalate (CaOx) nephrolithiasis is an adverse effect of Roux-en-Y gastric bypass surgery (RYGB). It is unknown when the increased risk for CaOx stone formation occurs after surgery.

      Methods

      We studied 13 morbidly obese adults undergoing RYGB with 24-hour urine collections at 4 weeks before and 1, 2, 4, and 6 months after surgery and computed CaOx relative saturation ratio (RSR) by EQUIL2.

      Results

      Eleven patients were female, mean±standard deviation age was 41.1±7.2 years, and none had diabetes or chronic kidney disease. Median (interquartile range) urinary oxalate excretion increased linearly from 12.6 (10.9–37.9) mg/24 hr at baseline to 28.4 (14.4–44.0) mg/24 hr at 6 months (slope = .188; P = .005). CaOx RSR increased significantly at 2 months after RYGB (1.4 [1.2–2.4] to 4.9 [1.7–10.0]; P = .017) and rose throughout the study to 5.7 (3.7–12.2) at 6 months (P = .001) with a positive linear slope (.255; P = .001). One patient had critical CaOx supersaturation (RSR = 34.7) and severe hyperoxaluria (101.7 mg/24 hr) at 6 months after RYGB. Significant decreases over time were seen in urine volume and sodium and potassium excretion, but no changes were noted in urinary pH, calcium, magnesium, or citrate.

      Conclusions

      Our data suggest that CaOx RSR, and thus risk for nephrolithiasis, rises as early as 2 months after RYGB and increases gradually in the first 6 months, largely because of reduced urine volume and increased urinary oxalate excretion. Interventions to reduce CaOx RSR, such as adequate fluid intake and agents to bind enteric oxalate, need to be evaluated in patients at risk for nephrolithiasis after RYGB.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Surgery for Obesity and Related Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sjöström L.
        • Narbro K.
        • Sjöström C.D.
        • et al.
        Effects of bariatric surgery on mortality in Swedish obese subjects.
        N Engl J Med. 2007; 357: 741-752
        • Sjöström L.
        • Lindroos A.K.
        • Peltonen M.
        • et al.
        Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
        N Engl J Med. 2004; 351: 2683-2693
      1. Buchwald H, Oien DM. Metabolic/bariatric surgery Worldwide 2008. Obes Surg 2009;19:1605–11.

        • Durrani O.
        • Morrisroe S.
        • Jackman S.
        • Averch T.
        Analysis of stone disease in morbidly obese patients undergoing gastric bypass surgery.
        J Endourol. 2006; 20: 749-752
        • Sinha M.K.
        • Collazo-Clavell M.L.
        • Rule A.
        • et al.
        Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery.
        Kidney Int. 2007; 72: 100-107
        • Nelson W.K.
        • Houghton S.G.
        • Milliner D.S.
        • Lieske J.C.
        • Sarr M.G.
        Enteric hyperoxaluria, nephrolithiasis, and oxalate nephropathy: potentially serious and unappreciated complications of Roux-en-Y gastric bypass.
        Surg Obes Relat Dis. 2005; 1: 481-485
        • Asplin J.R.
        • Coe F.L.
        Hyperoxaluria in kidney stone formers treated with modern bariatric surgery.
        J Urol. 2007; 177: 565-569
        • Nasr S.H.
        • D'Agati V.D.
        • Said S.M.
        • et al.
        Oxalate nephropathy complicating Roux-en-Y gastric bypass: an underrecognized cause of irreversible renal failure.
        Clin J Am Soc Nephrol. 2008; 3: 1676-1683
        • Liu X.
        • Lagoy A.
        • Discenza I.
        • et al.
        Metabolic and neuroendocrine responses to Roux-en-Y gastric bypass. I: energy balance, metabolic changes, and fat loss.
        J Clin Endocrinol Metab. 2012; 97: E1440-E1450
        • Encinosa W.E.
        • Bernard D.M.
        • Chen C.C.
        • Steiner C.A.
        Healthcare utilization and outcomes after bariatric surgery.
        Med Care. 2006; 44: 706-712
        • Werness P.G.
        • Brown C.M.
        • Smith L.H.
        • Finlayson B.
        EQUIL2: a BASIC computer program for the calculation of urinary saturation.
        J Urol. 1985; 134: 1242-1244
        • Pak C.Y.
        • Adams-Huet B.
        • Poindexter J.R.
        • Pearle M.S.
        • Peterson R.D.
        • Moe O.W.
        Rapid Communication: relative effect of urinary calcium and oxalate on saturation of calcium oxalate.
        Kidney Int. 2004; 66: 2032-2037
        • Singer J.D.
        • Willett J.B.
        Applied Longitudinal Data Analysis.
        Oxford University Press, New York2003
        • Armitage P.
        • Berry G.
        Statistical methods in medical research.
        Blackwell Scientific Publications, p, Oxford2003: 331
        • Maalouf N.M.
        • Tondapu P.
        • Guth E.S.
        • Livingston E.H.
        • Sakhaee K.
        Hypocitraturia and hyperoxaluria after Roux-en-Y gastric bypass surgery.
        J Urol. 2010; 183: 1026-1030
        • Matlaga B.R.
        • Shore A.D.
        • Magnuson T.
        • Clark J.M.
        • Johns R.
        • Makary M.A.
        Effect of gastric bypass surgery on kidney stone disease.
        J Urol. 2009; 181: 2573-2577
        • Patel B.N.
        • Passman C.M.
        • Fernandez A.
        • et al.
        Prevalence of hyperoxaluria after bariatric surgery.
        J Urol. 2009; 181: 161-166
        • Duffey B.G.
        • Alanee S.
        • Pedro R.N.
        • et al.
        Hyperoxaluria is a long-term consequence of Roux-en-Y gastric bypass: a 2-year prospective longitudinal study.
        J Am Coll Surg. 2010; 211: 8-15
        • Park A.M.
        • Storm D.W.
        • Fulmer B.R.
        • Still C.D.
        • Wood G.C.
        • Hartle 2nd, J.E.
        A prospective study of risk factors for nephrolithiasis after Roux-en-Y gastric bypass surgery.
        J Urol. 2009; 182: 2334-2339
        • Campfield T.
        • Braden G.
        • Flynn-Valone P.
        • Clark N.
        Urinary oxalate excretion in premature infants: effect of human milk versus formula feeding.
        Pediatrics. 1994; 94: 674-678
        • Wittgrove A.C.
        • Clark G.W.
        Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up.
        Obes Surg. 2000; 10: 233-239
        • Sakhaee K.
        • Poindexter J.R.
        • Griffith C.S.
        • Pak C.Y.
        Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
        J Urol. 2004; 172: 958-961
      2. Centers for Disease Control and Prevention (CDC). Vital signs: state-specific obesity prevalence among adults—United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:951–5.

        • Penniston K.L.
        • Kaplon D.M.
        • Gould J.C.
        • Nakada S.Y.
        Gastric band placement for obesity is not associated with increased urinary risk of urolithiasis compared to bypass.
        J Urol. 2009; 182: 2340-2346
        • Lieske J.C.
        • Goldfarb D.S.
        • De Simone C.
        • Regnier C.
        Use of a probiotic to decrease enteric hyperoxaluria.
        Kidney Int. 2005; 68: 1244-1249
        • Ortiz-Alvarado O.
        • Miyaoka R.
        • Kriedberg C.
        • Leavitt D.A.
        • Moeding A.
        • Stessman M.
        • Monga M.
        Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid in the management of hypercalciuric stone formers.
        Urology. 2012; 79: 282-286
        • Worcester E.M.
        • Coe F.L.
        Clinical practice. Calcium kidney stones.
        N Engl J Med. 2010; 363: 954-963
        • Kavanagh J.P.
        • Laube N.
        Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls?.
        J Urol. 2006; 175: 766-770
        • Tiwari R.
        • Campfield T.
        • Wittcopp C.
        • et al.
        Metabolic syndrome in obese adolescents is associated with risk for nephrolithiasis.
        J Pediatr. 2012; 160: 615-620